文献速递真菌感染

泊沙康唑浓度与儿童癌症及造血干细胞移植受者临床结局的关系

Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本系统综述检索四个数据库,纳入19项研究,评估儿童癌症或造血干细胞移植受者中泊沙康唑血清浓度与侵袭性真菌感染预防和治疗结局的相关性。预防方面突破性感染发生在血清浓度≤0.7 mg/L时,治疗方面谷浓度>1.0 mg/L与疗效无明确关联。证据质量差,需进一步研究确定治疗的最佳治疗靶标。

要点

  • 预防期间突破性侵袭性真菌感染发生在血清浓度≤0.7 mg/L时。
  • 治疗方面谷浓度>1.0 mg/L与疗效无明确关联。
  • 证据质量差,18篇论文偏倚风险中至高,1篇低。

核心结论

  • 本综述支持当前儿童肿瘤和HSCT受者泊沙康唑预防的建议。
  • 血清谷浓度与治疗疗效之间缺乏明确相关性,突显需进一步研究确定治疗的最佳治疗靶标。

研究设计与样本

  • 系统综述,检索Cochrane、Embase、MEDLINE和PubMed四个数据库,纳入涉及≤18岁接受癌症治疗或HSCT儿童并报告泊沙康唑血清浓度和治疗结局的研究。
  • 共纳入19项研究:12项报告泊沙康唑预防结局,2项报告治疗结局,5项同时报告两者。
  • 排除动物研究、主要针对>18岁成人人群的研究、非恶性疾病(除HSCT外)、病例报告、信件、社论、会议摘要和叙述性综述。
  • 使用Newcastle-Ottawa量表评估偏倚。

主要发现

  • 预防方面,突破性侵袭性真菌感染发生在1%-12%的儿童中,除一例外均发生在血清浓度≤0.7 mg/L时。
  • 治疗方面,谷浓度>1.0 mg/L与治疗疗效之间未观察到明确关联,血清浓度在0.2至4.8 mg/L范围内报告了不良结局。
  • 总体证据质量差:18篇论文偏倚风险中至高,1篇低风险;研究间侵袭性真菌感染定义存在差异。

局限性

  • 总体证据质量差:18篇论文偏倚风险中至高,1篇低风险。
  • 研究间侵袭性真菌感染定义存在差异。
  • 血清谷浓度与治疗疗效之间缺乏明确相关性,需进一步研究确定治疗的最佳治疗靶标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posaconazole is used to prevent and treat invasive fungal infections (IFIs) in immunocompromised children, including those undergoing cancer treatment or HSCT. Despite differences in pharmacokinetics and IFI epidemiology between children and adults, therapeutic targets established in adult studies are often applied to children. OBJECTIVES: This systematic review evaluated the correlation between serum posaconazole concentrations and clinical outcomes of IFI prophylaxis and treatment in children with malignancies or HSCT recipients. METHODS: Four databases (Cochrane, Embase, MEDLINE and PubMed) were searched for studies involving children (≤18 years old) receiving cancer treatment or HSCT that reported posaconazole serum concentrations and treatment outcomes. Animal studies, those primarily in adult (>18 years old) populations, non-malignant conditions (excluding HSCT), case reports, letters, editorials, conference abstracts and narrative reviews were excluded. Bias was assessed using the Newcastle-Ottawa scale. RESULTS: Nineteen studies were included: 12 reported outcomes of posaconazole prophylaxis; two of treatment; and five of both. For prophylaxis, breakthrough IFIs occurred in 1%-12% of children. All but one occurred with serum concentrations of ≤0.7 mg/L. For treatment, no clear association was observed between a trough concentration of >1.0 mg/L and treatment efficacy, with poor outcomes reported for serum concentrations ranging between 0.2 and 4.8 mg/L. Overall, quality of evidence was poor (medium to high risk of bias for 18 papers, low risk for 1 paper) and there was variation in IFI definitions across studies. CONCLUSIONS: This review supports current recommendations for posaconazole prophylaxis in paediatric oncology and HSCT recipients. The absence of a clear correlation found between serum trough concentrations and treatment efficacy highlights the need for further studies to determine optimal therapeutic targets for treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Weerdenburg H, Walker H, Haeusler GM, et al. Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2025. PMID: 40037294. doi:10.1093/jac/dkae473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。